EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of GAB1 in Cancer

Manuel Jesús Pérez-Baena iD, Francisco Josué Cordero-Pérez, Jesús Pérez-Losada iD, Marina Holgado-Madruga

Cancers · 20.08.2023 · 15 (16) · 4179

DOI: 10.3390/cancers15164179 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 20.08.2023. Verfasst von Manuel Jesús Pérez-Baena und 3 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, 37007 Salamanca, Spain. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JPL’s lab, MCIN/AEI/10.13039/501100011039, European Union Next Generation EU/PRTR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GRB2-associated binder 1 (GAB1) is the inaugural member of the GAB/DOS family of pleckstrin homology (PH) domain-containing proteins. Upon receiving various stimuli, GAB1 transitions from the cytoplasm to the membrane where it is phosphorylated by a range of kinases. This event recruits SH2 domain-containing proteins like SHP2, PI3K’s p85 subunit, CRK, and others, thereby activating distinct signaling pathways, including MAPK, PI3K/AKT, and JNK. GAB1-deficient embryos succumb in utero, presenting with developmental abnormalities in the heart, placenta, liver, skin, limb, and diaphragm myocytes. Oncogenic mutations have been identified in the context of cancer. GAB1 expression levels are disrupted in various tumors, and elevated levels in patients often portend a worse prognosis in multiple cancer types. This review focuses on GAB1’s influence on cellular transformation particularly in proliferation, evasion of apoptosis, metastasis, and angiogenesis—each of these processes being a cancer hallmark. GAB1 also modulates the resistance/sensitivity to antitumor therapies, making it a promising target for future anticancer strategies.

Schlagwörter

Stichwörter der Autor:innen

GAB1angiogenesismetastasistherapy resistancetumorigenesis

Autor:innen und Institutionen

  • Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, 37007 Salamanca, Spain.
  • Instituto de Investigación Biosanitaria de Salamanca (IBSAL), 37007 Salamanca, Spain.
  • Departamento de Medicina Interna, Complejo Asistencial de Zamora, 49022 Zamora, Spain.
  • Departamento de Fisiología y Farmacología, Universidad de Salamanca, 37007 Salamanca, Spain.
  • Instituto de Neurociencias de Castilla y León (INCyL), 37007 Salamanca, Spain.
  • Virtual Institute for Good Health and Well Being (GLADE), European Campus of City Universities (EC2U), 86073 Poitiers, France.

ORCID-Profile: Manuel Jesús Pérez-Baena, Jesús Pérez-Losada

Förderung

  • JPL’s lab
  • MCIN/AEI/10.13039/501100011039
  • European Union Next Generation EU/PRTR
  • Regional Government of Castile and León
  • FPU fellowship (MINECO/FEDER)

Zitieren

APA

Pérez-Baena, M. J., Cordero-Pérez, F. J., Pérez-Losada, J., & Holgado-Madruga, M. (2023). The Role of GAB1 in Cancer. Cancers, 15(16), 4179. https://doi.org/10.3390/cancers15164179

Vancouver

Pérez-Baena MJ, Cordero-Pérez FJ, Pérez-Losada J, Holgado-Madruga M. The Role of GAB1 in Cancer. Cancers. 2023;15(16):4179. doi:10.3390/cancers15164179

BibTeX
@article{PrezBaena2023,
  author = {Pérez-Baena, Manuel Jesús and Cordero-Pérez, Francisco Josué and Pérez-Losada, Jesús and Holgado-Madruga, Marina},
  title = {The Role of GAB1 in Cancer},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {16},
  pages = {4179},
  doi = {10.3390/cancers15164179}
}
Kostenlos starten →